Our mission

Transmural Biotech develops innovative products and services in the clinical field through image analysis technologies that allow personalized, economical, non-invasive and efficient medicine.

LEADERSWe are one of the 20 most important MedTech companies in the world.

VANGUARDWe develop medical technologies based on image diagnosis through artificial intelligence.

COMMITTED TO MEDICINEWe are committed to a personalized, predictive, non-invasive, rapid and reliable clinical diagnosis..

TRANSVERSAL We have international referenced scientific prescribers from different medical fields.

About us

Products

0

COUNTRIES
can benefit from our technology

0

CLINICS AND HOSPITALS
around the world provide our tests

0

DIAGNOSTIC TEST
successfully performed since 2016

0%

POSITIVE EXPERIENCES
of patients who have trusted us

Last News

The advances in medical technologies of Transmural Biotech have earned a place in the media. Our belief to the medicine of the future and our commitment to science are news.

The multicentre study of quantusFLM in ‘Nature’

“One of the most important ‘Nature’ scientific journals, ‘ScientificReports’, publishes a multicenter study – 790 patients from 20 centers – confirming that quantusFLM predicts fetal lung maturity with the same performance as invasive tests in amniotic fluid.

In the top 20 of the most innovative healthcare companies in the world

Transmural Biotech is among the most innovative healthcare companies of 2019, according to the ranking of the magazine «Technology Innovators». Our COO, Gabriela Fuentes, explains the value of AI in creating new medical technologies.

Prematurity is now predictable: quantusPREMATURITY has born

Spontaneous premature birth is one of the leading causes of infant mortality. For the first time, a test allows its prediction by analyzing an ultrasound image of the cervix that detects early cervical remodeling: quantusPREMATURITY.

They trust us

“One of the major challenges in the modern obstetrics has been to determine the Fetal Lung Maturity. But traditional methods based on amniocentesis have the limitation for being invasive and having the risk to cause premature rupture of membranes and preterm labor. quantusFLM is the solution to this clinical dilemma.”
Dr. Rogelio Cruz, Medicina Fetal México (Querétaro, Mexico)
“It is so amazing that we don’t need to analyze the amniotic fluid to determine the fetal lung maturity.”
Dr. Guillermo Azumendi, Centro Gutenberg (Málaga, Spain)
“Personalized, predictive and non-invasive medicine is the future”
Dr. Eduard Gratacós, BCNatal (Barcelona, Spain)
“quantusFLM lets us to know fetal lung maturity based on respiratory morbidity risk with a high reliability, that helps to end labor in the correct moment.”
Dr. Josué Zapata, Escuela Ecoimagen (Lima, Perú)

Our partners

Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!

Our partner

Our research and development work in medical technologies would not be possible without the collaboration of some of the main hospitals, health centers and specialized research groups in Spain and Latin America. Thanks for your support!

Contact us